Timeline: Two Years Of M&A Leading To Pfizer-Allergan Merger
This article was originally published in Scrip
Executive Summary
The deal to execute the biggest merger the pharmaceutical sector has ever seen is the culmination of a remarkable period of asset trading and M&A affecting many companies in the industry. Pfizer Inc. and Allergan PLC's combination, scheduled to complete in the second half of 2016, was preceded by numerous acquisitions making up the constituent parts of the company that will ultimately make up new Pfizer, and the path is also littered with failed deals and divestments, both completed and planned.